| Patent application number | Description | Published |
|---|
| 20080200371 | THIAZOLE AND THIADIAZOLE INHIBITORS OF TYROSINE PHOSPHATASES - Compounds and compositions are provided for modulating the activity of protein tyrosine phosphatases. In one embodiment, the compounds and compositions are thiazoles and thiadiazoles that inhibit the activity of protein tyrosine phosphatase 1B. | 08-21-2008 |
| 20090163468 | Fused Bicyclic mTor Inhibitors - Compounds represented by Formula (I) | 06-25-2009 |
| 20090197862 | 2-AMINOPYRIDINE KINASE INHIBITORS - 2-Aminopyridine compounds having the structure of Formula I, and pharmaceutically acceptable salts of these compounds. Compounds of Formula I inhibit the activity of tyrosine kinase enzymes in animals, including humans, and are useful in the treatment and/or prevention of various diseases and conditions. In particular, compounds disclosed herein are inhibitors of kinases, in particular, but not limited to, KDR, Tie-2, Flt3, FGFR3, Ab1, Aurora A, c-Src, IGF-1R, ALK, c-MET, RON, PAK1, PAK2, and TAK1, and can be used in the treatment of proliferative diseases, such as, but not limited to, cancer. The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The present invention is further directed to a method of treating a patient having a condition which is mediated by protein kinase activity by administering to the patient a therapeutically effective amount of the above-mentioned pharmaceutical composition. | 08-06-2009 |
| 20090197864 | Furo- and Thieno [3,2-c] Pyridines - Furo[3,2-c]Pyridine and Thieno[3,2-c]pyridine compounds of Formula I, and pharmaceutically acceptable salts thereof, preparation, intermediates, pharmaceutical compositions, and use, such as in disease treatment, including cancers, including conditions in which EMT is involved, including conditions mediated by protein kinase activity such as RON and/or MET. | 08-06-2009 |
| 20090286768 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES - Fused pyridine-based bicyclic compounds having the structure of Formula I, as defined herein, pharmaceutically acceptable salts thereof, preparation, compositions, and disease treatment therewith. This abstract does not define or limit the invention. | 11-19-2009 |
| 20100099679 | FUSED BICYCLIC mTOR INHIBITORS - Compounds represented by Formula (I) | 04-22-2010 |
| 20110190496 | FUSED BICYCLIC mTOR INHIBITORS - Compounds represented by Formula (I) | 08-04-2011 |
| 20110218183 | Fused Bicyclic mTOR Inhibitors - Compounds represented by Formula (I) | 09-08-2011 |
